DECEMBER SPEND £100+ GET 20% OFF
FREE NEXT DAY DELIVERY ON £20 SPEND*

Semax 5mg

£20.90
  • Batch HPLC tested at 99%+ purity.
  • Store frozen long term or in fridge when ready to be used.
  • 20% off purchases of ten or more.
  • Sold for research purposes only.
  • Contact us for Wholesale Orders.

 

Download COA here: Semax COA.pdf
Please note if you have a different Batch ID please contact us for the latest COA.

Click to Send Email

 

Semax

The mechanism of action of Semax is unknown.[2][3] It might interact with certain melanocortin receptors or inhibit enkephalinase enzymes.[2][3] Chemically, Semax is a peptide and a synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH).[4][5]

Though the exact mechanism of action of Semax is unclear, there is evidence that it may act through melanocortin receptors. Specifically, there is a report of Semax competitively antagonizing the action of the melanocortin receptor full agonist α-melanocyte-stimulating hormone (α-MSH) at the MC4 and MC5 receptors in both in vitro and in vivo experimental conditions, indicating that it may act as an antagonist or partial agonist of these receptors.[2] Semax did not antagonize α-MSH at the MC3receptor, though this receptor could still be a target of the drug.[2] As for the MC1 and MC2 receptors, they were not assayed.[2]In addition to actions at receptors, Semax, as well as a related peptide drug, Selank, have been found to inhibit enzymesinvolved in the degradation of enkephalins and other endogenous regulatory peptides (IC50 = 10 μM), though the clinical significance of this property is uncertain.[3]

As of November 2023, there are no published clinical trials involving Semax outside of Russia and post-Soviet states.[7]

References
  1. Voronina TA (2023). “Cognitive Impairment and Nootropic Drugs: Mechanism of Action and Spectrum of Effects”. Neurochemical Journal. 17 (2): 180–188. doi:10.1134/S1819712423020198. ISSN 1819-7124.
  2. Bertolini A (March 2012). “Drug-induced activation of the nervous control of inflammation: a novel possibility for the treatment of hypoxic damage”. European Journal of Pharmacology. 679 (1–3): 1–8. doi:10.1016/j.ejphar.2012.01.004. PMID 22293371.
  3. Kost NV, Sokolov OI, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, et al. (2001). “Semax and selank inhibit the enkephalin-degrading enzymes from human serum”. Bioorganicheskaia Khimiia (in Russian). 27 (3): 180–183. doi:10.1023/A:1011373002885. PMID 11443939. S2CID 26029820.
  4. Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM (March 2022). “Development of Peptide Biopharmaceuticals in Russia”. Pharmaceutics. 14 (4): 716. doi:10.3390/pharmaceutics14040716. PMC 9030433. PMID 35456550.
  5. Potaman VN, Alfeeva LY, Kamensky AA, Levitzkaya NG, Nezavibatko VN (April 1991). “N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes”. Biochemical and Biophysical Research Communications. 176 (2): 741–746. doi:10.1016/S0006-291X(05)80247-5. PMID 1851003.
  6. “Home”. AdisInsight. Retrieved 3 September 2024.
  7. “Semax – Search Results – PubMed”. PubMed. Retrieved 2023-11-12.

Keywords: Semax.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop